AstraZeneca holds talks with US cancer drug developer in $400bn merger

AstraZeneca, Britain's biggest drugmaker, is in talks to acquire US pharmaceutical rival Bristol Myers Squibb, known for its cancer treatments. Per The Guardian, the potential merger would create the world's fourth-largest drug manufacturer with a combined value of approximately four hundred billion dollars.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton